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Conclusion. BMP-7 partially reversed diabetic-induced kid-Bone morphogenic protein-7 (BMP-7), a novel therapy for
ney hypertrophy, restoring GFR, urine albumin excretion, anddiabetic nephropathy.
glomerular histology toward normal. Restoration of BMP-7Background. Bone morphogenic protein-7 (BMP-7), an es-
expression was associated with a successful repair reaction andsential developmental renal morphogen, is a secreted differen-
a reversal of the ill-fated injury response.tiation factor of the adult collecting duct. It activates receptors
in the collecting duct, distal nephron, proximal tubule, and
glomerulus. BMP-7 is therapeutic in tubulointerstitial nephritis
raising the question of broader efficacy in chronic kidney dis- Recent studies have made the surprising observationease (CKD).
that a renal tubular developmental morphogen, boneMethods. Diabetes was induced in 200 g rats by a single dose
morphogenetic protein-7 (BMP-7), was effective in pre-of streptozotocin. After 16 weeks, glomerular hypertrophy and
proteinuria were established, and therapy with BMP-7 (10, 30, venting the tubulointerstitial nephritis stimulated by ob-
or 100 g/kg intravenously twice a week), enalapril (20 mg/kg), structive uropathy [1]. The mechanism of action appeared
or vehicle was begun and continued until 32 weeks. Kidney to be preservation of epithelial cell phenotype, inhibitionweight, glomerular filtration rate (GFR), urine albumin excre-
of epithelial-mesenchymal transdifferentiation, and inhi-tion, blood pressure, pathology, and BMP-7 expression were
bition of injury-induced epithelial cell apoptosis. Thesemeasured.
Results. Diabetic vehicle-treated rats developed renal insuf- actions of BMP-7 are reminiscent of the effects that the
ficiency by 32 weeks (GFR, 0.34  0.02 mL/min/100 g body morphogen exercises during development.
weight vs. 0.55  0.02 in normal). In the diabetic BMP-7 high- During vertebrate development, the permanent kid-dose–treated rats, GFR was preserved (0.70  0.08, P  0.01
ney is generated by the interactions of the ureteric budvs. vehicle), and higher than diabetic enalapril-treated rats
and the metanephric mesenchyme [2, 3]. BMP-7 has been(0.58  0.06). Kidney weights of vehicle-treated animals were
not affected, but were reduced in all of the treatment groups shown to be a required factor leading to the condensation
(P  0.001). Proteinuria was reversed to normal by BMP-7 in and epithelialization of the metanephric mesenchyme,
a dose-dependent manner. The reduction in proteinuria by the and the reciprocal induction of collecting duct differenti-intermediate dose of BMP-7 was similar to the effect of enala-
ation [4–6]. It is expressed in the ureteric bud and in thepril therapy. Glomerular area and interstitial volume were sig-
condensing mesenchyme at day 11.5 post-coitum. BMP-7nificantly decreased in the BMP-7 and enalapril-treated ani-
mals. Glomerular sclerosis was prevented by BMP-7 therapy is a survival factor for the condensing mesenchymal cells,
more effectively than by enalapril. Enalapril controlled hyper- which die between 12.5 and 14.5 days post-coitum in its
tension throughout the course of therapy while BMP-7 did not absence [4]. At day 12 post-coitum, in the absence ofaffect blood pressure until the final 4 weeks of therapy. Diabetic
BMP-7, glomerulus formation ceases as the mesenchy-vehicle-treated rats lost BMP-7 expression in the kidney.
mal cells apoptose. At birth, BMP-7–deficient kidneysBMP-7 and enalapril therapy restored BMP-7 expression at
high levels. are dysgenic, hypoplastic, and cystic with severely dilated
collecting ducts separated by areas of stromal cells and
extracellular matrix. The kidneys are hydronephrotic,
1 Professor Robert Chevalier served as a guest editor for this paper. and they do not have metanephric mesenchyme or evi-2 Song Wang and Qing Chen contributed equally to this project.
dence of glomerulus formation in the cortical nephro-
Key words: BMP-7, diabetic nephropathy, chronic kidney disease. genic zone [4, 5]. Cysts appear to originate from deriva-
tives of the ureteric bud, suggesting abnormal activity ofReceived for publication October 10, 2002
the cell cycle and disordered polarity in these cells. Glo-and in revised form December 18, 2002
Accepted for publication February 3, 2003 merular density is less than three per section compared
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Compared to many other morphogens, expression of napolis, IN, USA). Body weights were taken once a
week. Food and water intake were monitored daily.BMP-7 in the tubular epithelial segments derived from
the ureteric bud does not cease following its develop- Renal hypertrophy was well developed at 16 weeks
prior to treatment with vehicle, BMP-7, or enalapril. Atmental inductive actions, rather its expression persists
and it likely functions physiologically as a collecting duct 16 weeks, animals were divided into eight groups. Group
1 animals had 16 weeks of diabetes mellitus. Group 2epithelial cell differentiation factor. As such, it inhibits
proliferation by blocking progress of the cell cycle at the animals were 16 weeks of normal controls. Group 3 dia-
betic animals were treated with tail-vein injection of vehi-G1 checkpoint and it prevents apoptosis [1, 8].
Tissue injuries frequently stimulate attempts at repair cle twice a week for 16 weeks. Group 4, group 5, and
group 6 were diabetic animals treated with tail-vein injec-that recapitulate development, including entry of surviv-
ing tissue cells into the cell cycle. This would require the tions of BMP-7, 100, 30, and 10 g/kg body weight, re-
spectively, twice a week for 16 weeks. Group 7 animalsactions of differentiation factors to be overcome perhaps
by decreasing their levels. In turn, the absence of key were treated with enalapril (20 mg/kg) through the drink-
ing water for 16 weeks. Group 8 animals were normalfactors could cause these attempted repairs to default
into a fibrotic process, resulting in permanent loss of the controls maintained for 32 weeks alongside the diabetic
animals. Group 1 and group 2 animals were sacrificedstarting tissue. Unsuccessful injury repair characterizes
many renal diseases that lead to loss of excretory func- at 16 weeks. The others were sacrificed at 32 weeks. All
treatments began at 16 weeks and continued through 32tion. Recently, renal injuries, including those caused by
high glucose levels, have been shown to decrease BMP-7 weeks. Glomerular filtration rate (GFR), urine albumin
excretion, kidney weight, glomerular area, mesangial ma-levels [1, 9–11]. Treatment of two of these injuries with
BMP-7 prevented renal tubular atrophy and epithelial trix area, interstitial volume, monocyte and macrophage
infiltration, thickness of glomerular basement membranecell apoptosis [1, 11]. Failure of tubular development
and mesenchymal apoptosis are features of development (GBM), and glomerulosclerosis were measured.
in the BMP-7–deficient state.
Renal functionHerein we report in a proof of concept study that
BMP-7 is an effective therapy for diabetic nephropathy. In all animals, GFR was measured as the clearance of
inulin as previously described [1]. Rats were anesthetizedTherapy of diabetic nephropathy with BMP-7 partially
reversed the renal injury induced by diabetes and hyper- with a ketamine/xylazine cocktail. A catheter was in-
serted into the femoral vein under a dissecting micro-glycemia, and it prevented the development of glomeru-
losclerosis. While both agents were efficacious, BMP-7 scope for infusion. Another catheter was placed into the
femoral artery for collecting blood samples. Urine waswas more effective in reversing proteinuria and preventing
glomerulosclerosis. Diabetic injury resulted in the loss collected by bladder cannulation.
After the completion of surgery, a bolus of 2 mL/kgof tubular epithelial and glomerular podocyte phenotype
manifested by loss of BMP-7 expression, and therapy of 3% inulin (Cypros Pharmaceutical Corp., Carlsbad,
CA, USA) and 0.2% p-aminohippurate (PAH) in nor-with BMP-7 restored the phenotype of the collecting
duct manifested by restoration of BMP-7 expression. mal saline was infused as a priming load, followed by a
sustaining infusion of the same solution at the rate of 8
mL/hour/kg. Urine collection was initiated for three 20-
METHODS
minute collection periods after an hour of equilibration.
Animals An arterial blood sample was obtained during each clear-
ance period. Plasma and urine were analyzed for inulin.Female Sprague-Dawley rats 10 weeks of age weighing
190 to 220 g were used. Animals were allowed free access
Urine albumin excretionto standard rat chow and to tap water. Diabetes mellitus
was induced by a single tail-vein injection of streptozo- Before the clearance study, the rats were placed in
individual metabolic cages for two 24-hour urine collec-tocin (STZ) (62 mg/kg of body weight) (Sigma Chemical
Company, St. Louis, MO, USA) at day 0. The diabetic tions. Urine volume was measured and urinary protein
concentration was determined with a Bio-Rad proteinstate was confirmed 72 hours later by the determination
of blood glucose concentration 300 mg/dL. From day assay (Hercules, CA, USA).
3, all the diabetic rats received daily subcutaneous injec-
Preparation of kidneystions of 1.0 to 7.0 U human recombinant long-acting
insulin injection (Eli Lilly & Co., Indianapolis, IN, USA) After the clearance studies, the rats were euthanized.
Both kidneys were rapidly removed and placed in ice-as required to maintain the blood glucose concentration
between 300 and 500 mg/dL. Tail blood glucose levels cold phosphate-buffered saline (PBS). Kidneys were
weighed and then sliced on a cold glass plate. Two 2 mmwere measured twice a week with an Accu–ChekTM Ad-
vantage Meter (Roche Diagnostic Corporation, India- coronal sections were immersed in Histochoice (Sigma
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Chemical Company) and in 10% buffered formalin. Kid- In situ hybridization
ney sections were embedded in paraffin and cut at 3 Briefly, as previously described [14], frozen sections
m and stained with hematoxylin and eosin, Gomori’s (4 to 6 ) were fixed in 4% formaldehyde in PBS for 20
trichrome and periodic acid-Schiff (PAS). minutes at room temperature. Sections were washed
once in PBS at three times the normal concentration of
Renal morphology
salt. Sections were then washed three times in PBS for
The morphometric analysis was done in a blind man- 5 minutes and in water for 2 minutes and once in 0.1
ner. Osteomeasure (Osteometrics, Atlanta, GA, USA) mol/L triethanolamine, pH 8.0, for 10 minutes. Addi-
was used for morphometric analysis. Glomeruli were tional washings for 10 minutes in 0.25% acetic anhydride
traced at 400 magnification. Tissue sections stained by in 0.1 mol/L triethanolamine, pH 8.0, and twice for 2
PAS were used. The measured glomerular parameters minutes in 2  standard sodium citrate (SSC) were per-
were (1) glomerular area, determined out of 60 glomeruli formed. The sections were then dehydrated through
per group, which had vascular pole on it from randomly graded ethanols followed by air-drying for 5 minutes.
selected sections; (2) mesangial matrix area (defined as This was followed by vacuum drying for 1 hour at room
PAS-positive material in the mesangium); (3) ratio of temperature. Each slide was then hybridized for 18 hours
the mesangial matrix area to the glomerular area; and (4) at 60C with 106 counts/minute of 33P-radiolabeled ribo-
focal segmental glomerulosclerosis (glomerular sclerosis probe in 80L of hybridization mixture [50% formamide,
was defined as global sclerosis or segments of glomerular 2% Denhardt’s solution, 10% dextran sulfate, 0.3 mol/L
tufts demonstrating collapsed, obliterated capillaries with NaCl, 10 mmol/L Tris, pH  8.0, 2 mmol/L ethylene-
sparseness of normal cellular elements). The percent of diaminetetraacetic acid (EDTA), and 0.25 g/mL tRNA].
sclerotic glomeruli was determined out of 150 glomeruli The sense and antisense probes for BMP-7 were a kind
per animal from randomly selected sections [12]. gift of Kuber Sampath. Slides were then treated for 20
Interstitial volume was determined by a point-count-
minutes in 4  SSC at room temperature; 4  SSC for
ing technique on tissue sections stained by the Gomori’s
5 minutes at room temperature; RNase A (20 g/mL)
trichrome method and was expressed as the mean per-
for 30 minutes at 37C in 0.5 mol/L NaCl, 0.01 mol/L
centage of grid points laying within the interstitial area
Tris, pH  8.0, and 1 mmol/L EDTA; twice 2  SSCin up to five fields in the cortex [1, 13].
for 5 minutes at room temperature; 1  SSC for 10Quantitation of monocyte/macrophage infiltration was
minutes at room temperature; 0.5  SSC for 10 minutesdetermined by counting ED-1 antigen–positive cells in
at room temperature; and 0.1  SSC for 30 minutes attissue sections [1, 13]. Kidneys were fixed in Histochoice,
60C. The sections were then dehydrated using increas-paraffin embedded, and sectioned. Sections were de-
ing concentrations of ethanol, followed by vacuum desic-waxed and rehydrated prior to incubation with the ED-1
cation for 30 minutes. Slides were dipped in liquid photo-antibody obtained from Harlan (Indianapolis, IN, USA).
graphic emulsion (Kodak NTB2; Kodak, Rochester, NY,The location of the primary antibodies was visualized
USA) and exposed for 1 week at 4C. After development,using alkaline phosphatase-linked second antibody. To
slides were counterstained with hematoxylin and eosin.obtain numbers of infiltrating monocyte/macrophage in
the glomeruli, 50 consecutive cross-sections of glomeruli
Statistical analysis
of each animal were evaluated. To obtain numbers of
Results were expressed as mean  SEM. Statisticalinfiltrating monocyte/macrophage in the renal cortical
analysis was carried out by using a one-way analysis oftubulointerstitium, 10 consecutive nonoverlapping fields
variance (ANOVA). Statistical significance was achievedwere counted in each section and viewed at400 magni-
if the P  0.05.fication.
Electron microscopy
RESULTS
Fresh tissue was fixed in 3% (wt/vol) glutaraldehyde
General group comparisonsbuffer and postfixed in OsO4. Tissue was then dehydrated
There were eight groups of animals in the study, andin ethanol and embedded in poly/bed 812 resin (Poly
the number of animals in each group, their body weightsScience, Inc., Warrington, PA, USA). Thin sections were
at the beginning and at the study end, their blood glucosestained with uranyl acetate and lead citrate and exam-
concentrations, insulin doses, and the mortality data forined using a transmission electron microscope.
each group are summarized in Table 1. There were no
Blood pressure determinations significant differences in body weight gain between the
different groups during the 16 weeks of treatment. AlsoThe tail artery cuff method was used to follow blood
pressures. there were no significant differences in blood glucose
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levels between the different 32-week diabetic rats that
received various treatments during the 16-week treat-
ment period. We increased the insulin doses during the
study to increase blood glucose control in order to de-
crease the mortality we were encountering. Specifically,
the blood glucose range was decreased from 400 to 600
to 300 to 500. As a result, the blood glucose levels were
significantly higher in the 16-week diabetic group than
those of all the 32-week treatment groups, and insulin
doses in the 16-week diabetic group were significantly
lower than those of all the 32-week treatment groups
(P  0.01). The animals in the high-dose BMP-7 group
had more severe diabetes requiring slightly higher doses
of insulin to maintain the same level of blood glucose.
The mortality observed in the various treatment groups
was similar. The causes of death were hypoglycemia,
ketoacidosis, and anesthesia. Some animals died of un-
known reasons because the biochemical data on the day
of death were lacking, and autopsies were not informa-
tive, suggesting ketoacidosis or hypoglycemia as the
causes. All of the deaths occurred between 20 and 32
weeks. Since our primary end point was GFR, none
of the premature dead animals were included in the
analysis.
Characterization of the streptozotocin diabetic
nephropathy model
The effects of diabetes on kidney weight and GFR
are shown in Figure 1. Diabetes mellitus was induced at
week 0. At 16 weeks of diabetes, kidney weight had
increased 1.8-fold compared to normal (1.45  0.02 g
vs. 0.81  0.02 g, P  0.001), while GFR increased 2.9-
fold compared to normal (1.42  0.24 mL/min/g body
weight vs. 0.49  0.04 mL/min/100 g body weight, P 
0.001). These data demonstrated that we had induced
significant kidney hypertrophy and glomerular hyperfil-
tration in this animal model. All treatments began at
16 weeks and continued through 32 weeks (or for an
additional 16 weeks).
After 16 weeks of vehicle treatment, the kidney weights
were not changed (1.44 0.04 g vs. 1.45 0.02 g) (Fig. 1).
But the GFR of vehicle-treated diabetic rats was de-
creased 75% to lower than normal rats maintained for
32 weeks (0.340.02 mL/min/100 g body weight vs. 0.55
0.02 mL/min/100 g body weight). This demonstrated that
without treatment there was a change from renal hyper-
filtration to renal failure in control rats during the treat-
ment period.
Effects of therapy on kidney hypertrophy
As shown in Figure 2, kidney weights of BMP-7- and
enalapril-treated animals were significantly decreased
(1.10  0.03 in the BMP-7 high-dose group, 1.09  0.04
in the enalapril-treated group) compared to the diabetic
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vehicle-treated rats (P  0.001). There was a dose-
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Fig. 2. Effects of bone morphogenic protein-7 (BMP-7) and enalapril
treatments on diabetes mellitus–induced renal hypertrophy. Diabetes
mellitus was induced at week 0. Treatment of BMP-7 or enalapril, or
vehicle was began at week 16 and finished at week 32. At 16 weeks,
kidney weight increased to 1.45 g in diabetes mellitus compared to
normal. After 16 weeks of vehicle treatment, the kidney weight was
still elevated (1.44  0.04 g). The kidney weights of the BMP-7- and
enalapril-treated groups were significantly decreased to 1.10  0.03 in
BMP-7 high-dose group and 1.09  0.04 in enalapril-treated group,
compared to diabetes mellitus vehicle treated. ***P  0.001, normal
compared to 32-week diabetes mellitus vehicle treated; ***P  0.001,
diabetes mellitus compared to all the other treatment groups. Symbols
are: () normal; () diabetes mellitus; () BMP-7, 10 g/kg body
weight; () BMP-7, 30 g/kg body weight; () BMP-7, 100 g/kg body
weight; () enalapril, 20 mg/kg body weight.
vs. 0.34  0.02, P  0.01). These data indicated that the
vehicle control group had developed progressive renalFig. 1. The long-term streptozotocin (STZ)-induced model of diabetic
failure during the 16 weeks of vehicle, while the treat-nephropathy. Diabetes mellitus was induced at week 0 and the rats
maintained as described in the Methods section. (A) At 16 weeks, ment groups had partial reversal of kidney hypertrophy
kidney weights had increased 1.8 fold in diabetes mellitus compared to and prevention of further injury resulting in GFRs sig-normal (1.45  0.02 g vs. 0.81  0.02 g). (B) Glomerular filtration rate
nificantly greater than normal at the high dose BMP-7(GFR) also increased 2.9-fold compared to normal (1.42  0.24 mL/
min/100 g body weight vs. 0.49  0.04 mL/min/100 g body weight). and dose dependently decreasing to normal with de-
After 16 weeks of vehicle treatment, kidney weights had not changed creasing BMP-7 doses.significantly (A), but the GFR was decreased 75% to significantly lower
than normal at 32 weeks (0.34  0.02 vs. 0.55  0.02) (B). Symbols
Urine albumin excretionare: () normal; () diabetes mellitus. ***P  0.001 compared to
normal at the same time point. The effects of diabetes and treatment on urine albumin
excretion are shown in Figure 4. Diabetic rats exhibited
a pronounced increase in urine albumin excretion rate
compared with nondiabetic rats at both 16 weeks (59.70dependent ordering of kidney weights in the BMP-7–
16.71 mg/day vs. 3.76  0.39 mg/day) and 32 weekstreated group (1.19  0.03, 1.19  0.03, and 1.10  0.03,
(174.44 52.50 vs. 8.24 1.28, P 0.001). This responserespectively). These data demonstrated that BMP-7 and
to diabetes was reversed by BMP-7 and enalapril treat-enalapril treatment partially reversed diabetic renal hy-
ment (P  0.05, diabetes mellitus vs. BMP-30 and enala-pertrophy.
pril; P 0.01, diabetes mellitus vs. BMP-100). There wasWhile kidney weight was not affected by 16 weeks of
a significant dose-dependent ordering of urine albuminvehicle treatment, GFR was reduced from 1.42  0.24
excretion in the BMP-7–treated groups (59.46  21.84,mL/min/100 g body weight to 0.34  0.02 mL/min/100 g
33.02  9.11, and 14.27  3.50, respectively).body weight, which was 40% reduced from normal of
0.55  0.02 mL/min/g body weight (Figs. 1 and 3). The
Treatment effects on pathologyGFR in the BMP-7 and enalapril treatment groups were
Compared to normal, kidneys of 16-week diabetic ratsnormal or greater (Fig. 3). The GFR of the BMP-7 high-
had massive glomerular hypertrophy to go along withdose group was significantly greater than the GFR of
the 32-week diabetic vehicle-treated group (0.70  0.08 the increase in kidney weights (Fig. 5). The 16-week
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Fig. 3. Effects of bone morphogenic protein-7 (BMP-7) and enalapril Fig. 4. Effects of bone morphogenic protein-7 (BMP-7) and enalapriltreatments on glomerular filtration rate (GFR). In diabetic rats the treatments on urine albumin excretion in diabetes mellitus. DiabetesGFR was increased 2.9-fold compared to normal at 16 weeks (1.42  mellitus was induced at week 0. Treatment of BMP-7 or enalapril or0.24 mL/min/100 g body weight vs. 0.49  0.04 mL/min/100 g body vehicle was began at week 16 and finished at week 32. Diabetic ratsweight, P  0.001), but by 32 weeks the GFR was decreased to lower exhibited a pronounced increase in albumin excretion rate comparedthan normal during vehicle treatment (0.34  0.02 vs. 0.55  0.02). The with nondiabetic rats at both 16 weeks (59.70  16.71 mg/day vs. 3.76 BMP-7 and enalapril treatments restored GFR to normal or slightly 0.39 mg/day) and 32 weeks (174.4  52.50 vs. 8.24  1.28, ***P above normal. The GFRs of the BMP-7 high-dose animals were signifi- 0.001). This response to diabetes mellitus was markedly reduced bycantly greater than the GFR of diabetes mellitus group (vehicle-treated) BMP-7 and enalapril treatment. There was a dose-dependent inverse(0.70  0.08 vs. 0.34  0.02, P  0.01). There was a dose-dependent order in the levels of urinary protein in the BMP-7–treated groups fromorganization of the GFR by ascending doses in the BMP-7–treated low- to high-dose (59.46  21.84, 33.02  9.11, and 14.27  3.50,groups (0.59  0.07, 0.62  0.09, and 0.70  0.08, respectively). **P  respectively). The enalapril treatment group had urinary albumin excre-0.01, BMP-7 high-dose compared to 32-week diabetes mellitus vehicle- tion levels similar to the intermediate-dose BMP-7 group. *P  0.05,treated; ***P  0.001, 16-week diabetes mellitus compared to 16-week diabetes mellitus vs. BMP-30 and enalapril; **P 0.01, diabetes mellitusnormal and all the 32-week groups. vs. BMP-100. Symbols are: () normal; () diabetes mellitus; () BMP-7,
10 g/kg body weight; () BMP-7, 30 g/kg body weight; () BMP-7,
100 g/kg body weight; () enalapril, 20 mg/kg body weight.
diabetic kidneys also had mild increases in mesangial
matrix and thickening of glomerular and tubular base-
Morphometric parametersment membranes (Fig. 5) in agreement with previous
studies [15]. By 32 weeks of diabetes, the kidneys of The effect of diabetes and the various treatments on
vehicle-treated rats continued to be hypertrophied, but glomerular area are shown in Figure 7A. Diabetic rats
a significant component of glomerular area was sclerotic vehicle-treated had a massively larger glomerular area
in a focal segmental pattern (Figs. 5 and 6). The sclerotic than normal control rats (1.28 0.03 104 m2 vs. 0.90
areas demonstrated increased matrix, obliteration of 0.02  104 m2, P  0.001) concordant with their in-
capillaries, and sparseness of cellular elements. Electron creased kidney weights. All the treatments except vehicle
partially reversed the glomerular hypertrophy (P microscopy confirmed the increase in GBM thickness
produced by diabetes by 16 weeks as shown in Figure 5. 0.001). The mesangial matrix area was also increased in
diabetic rats compared to all the BMP-7 and enalaprilThe focal segmental nature of glomerular sclerosis in
STZ diabetic nephropathy is a known deviation from treatment groups, but the ratio of mesangial matrix area
to glomerular area were not different between differentthe human disease pathology of a diffuse global sclerosis
with intermittent Kimmelstiel-Wilson nodular glomeru- groups (data not shown).
As shown in Figure 7B, the cortical interstitial volumelar sclerosis lesions [16]. This difference has been pre-
viously documented [12, 16]. was increased from 9.0  0.6% in nondiabetic rats to
13.1  0.7% in the diabetic rats. High-dose BMP-7 andTreatment with BMP-7 prevented the development of
glomerulosclerosis along with a dose-dependent reduc- enalapril treatments significantly reduced the increase
in interstitial volume to 10.7  0.3%, and 10.3  0.4%,tion in the accumulation of mesangial matrix such that
the intermediate- and high-dose BMP-7 treatments were respectively. Diabetes mellitus significantly increased the
monocyte/macrophage infiltration both in the glomeruliassociated with near normal glomerular histology except
for incomplete resolution of glomerular hypertrophy (2.08  0.24 vs. 1.01  0.17, P  0.01) and in the cortical
tubulointerstitium (7.25 0.51 vs. 4.30 0.35, P 0.001)(Figs. 5 to 7). Enalapril therapy was less effective in
preventing glomerulosclerosis, and it was less effective compared to normal rats. BMP-7 and enalapril treatment
decreased the tubulointerstitial infiltration. Overall, thethan intermediate or high dose BMP-7 in eliminating
accumulation of mesangial matrix (Fig. 5). level of monocyte/macrophage infiltration in this model
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Fig. 5. Coronal sections of kidneys stained with periodic acid-Schiff (PAS) to highlight basement membranes and mesangial matrix. (A ) A section
of a kidney from a 16-week normal animal. (B ) A section of a kidney from a 16-week diabetic animal. Glomerular hypertrophy and early increases
in mesangial matrix were present. There was evidence of glomerular (arrow) and tubular (arrow) basement membrane thickening. (C ) A section
of a kidney from a 32-week diabetic vehicle-treated animal. One glomerulus is sclerotic and both are hypertrophied. There are segments of
collapsed glomerular tuft with sparseness of normal cellular elements. (D ) A section of a kidney from an animal treated with bone morphogenic
protein-7 (BMP-7), 30 g/kg body weight, administered intravenously twice a week. (E ) A section of a kidney from an animal treated with BMP-7,
100 g/kg body weight, administered intravenously twice a week. (F ) A section of a kidney from an animal treated with enalapril, 20 mg/kg body
weight. All of the three BMP-7 dosages and enalapril treatment decreased glomerular sclerosis, but the enalapril treatment had more mesangial
matrix accumulation.
was low, and it represented a very early phase of tubulo- compared with nondiabetic rats at 32 weeks (10.7 
4.0% vs. 0.7 0.2%, P 0.001). This degree and type ofinterstitial nephritis and glomerular inflammation.
The effect of diabetes, BMP-7, or enalapril treatment glomerulosclerosis is similar to that reported in previous
studies with STZ diabetes mellitus [12, 16]. Glomerulo-on glomerular pathology is shown in Figure 8. Focal
segmental glomerulosclerosis developed in diabetic rats sclerosis was markedly reduced by BMP-7 and less so
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Fig. 6. Coronal sections of kidneys stained with Gomori’s trichrome for collagen. With this stain, collagen fibrils stain blue, whereas the cells stain
red. (A and B ) Sections from kidneys of two normal control animals maintained in the animal facility with the diabetic animals for 32 weeks. (C )
A section from a diabetic vehicle-treated animal. Arrow shows early interstitial matrix accumulation. The glomeruli are hypertrophic and one has
segmental sclerosis. (D, E, and F ) Sections of kidneys from animals treated with bone morphogenic protein-7 (BMP-7), 10, 30, and 100 g/kg
body weight, administered intravenously twice a week, respectively. Kidneys from the 10 g/kg body weight–dose animals had greater mesangial
matrix accumulation than the two higher doses, which were very similar to normal except for residual glomerular hypertrophy.
by enalapril treatment. There was a dose-dependent or- uted to control of hypertension in diabetes [17–20].
Therefore, we compared blood pressures between thedering of the reduction in glomerulosclerosis in the BMP-7
various treatment groups in this study. As shown in Fig-treated groups (4.1  1.4%, P  0.05; 3.5  0.8%, P 
ure 9, the 16-week diabetic rats were mildly hypertensive0.01; and 2.1  0.3%, P  0.001, respectively) (Fig. 8).
in agreement with previous studies. Mean systolic blood
Mechanism of BMP-7 action pressures were 160  3 mm Hg compared to 141  4
A significant component of the renoprotective actions mm Hg in normal control rats [16]. By 20 weeks, enalapril
therapy had reversed the hypertension of the diabetic rats,of the positive control in these studies, enalapril, is attrib-
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Fig. 7. Effects of bone morphogenic protein-7
(BMP-7) and enalapril (ENP) treatments on
glomerular and interstitial areas in diabetic
(DM) rats. (A) Glomerular area. Diabetic rats
had a significantly larger glomerular area than
normal control rats (1.28  0.03  104 m2
vs. 0.90  0.02  104 m2; ***P  0.001). All
the treatment groups partially reversed the
glomerular hypertrophy (***P  0.001). (B)
Interstitial area. The cortical interstitial area
was increased from 9.0  0.6% sections in
nondiabetic rat kidneys to 13.1  0.7% in the
diabetic rats (***P 0.001). The BMP-7 high-
dose and enalapril treatment significantly de-
creased interstitial area (10.7  0.3%, *P 
0.05; 10.3  0.4%, **P  0.01, respectively)
when compared to vehicle-treated diabetes
mellitus.
Fig. 9. Effects of enalapril and bone morphogenic protein-7 (BMP-7)
therapies on systolic blood pressure of diabetic rats. Blood pressures
were obtained by the tail artery cuff method. By 16 weeks, the diabetic
animals were significantly hypertensive. The hypertension was stable
in vehicle-treated rats until week 28 when systolic blood pressures began
to increase again. Over 2 months, enalapril therapy restored blood
pressure to normal. BMP-7 therapy did not affect blood pressure until
Fig. 8. Effects of bone morphogenic protein-7 (BMP-7) and enalapril the last 4 weeks of therapy. Data represent mean blood pressures for
(ENP) treatments on glomerulosclerosis. Diabetic (DM) rats exhibited respective groups. The error bars were eliminated to simplify the figure.
a significant increase in prevalence of sclerotic glomeruli compared with Symbols are: () normal; () diabetes mellitus; () BMP-7, 100 g/kg
nondiabetic rats at 32 weeks (10.7  4.0% vs. 0.7  0.2%, ***P  body weight; () enalapril. *P  0.05; ***P  0.001.
0.001). This response was markedly reduced by BMP-7 and enalapril
treatment. There was a dose-dependent ordering in the BMP-7–treated
groups (4.1  1.4%, *P  0.05; 3.5  0.8%, **P  0.01; and 2.1 
0.3%, ***P  0.001, respectively). The effect of high-dose BMP-7 was
significantly better than that of enalapril. enabling the ill-fated injury response to be initiated. This
turned out to be so as shown in Figure 10. In the normal
rat kidney, BMP-7 is expressed in the medulla, the corti-
cal collecting ducts, and glomerular podocytes [21]. By
and enalapril therapy maintained normotension through- 16 weeks of diabetes, BMP-7 expression was absent from
out the rest of the 32 weeks. In contrast, BMP-7 therapy the kidney, and this absence was maintained during ther-
had no effect on blood pressure until after 28 weeks apy with vehicle (Fig. 10). Treatment with either BMP-7
when it began to cause reductions in hypertension until, or enalapril restored BMP-7 expression in its normal
at 32 weeks, blood pressures were normalized in the pattern at high levels (Fig. 10). Thus, BMP-7 and enala-
BMP-7 high-dose–treated animals. At 32 weeks, the dia- pril therapy stimulated a successful repair reaction
betic vehicle-treated rats exhibited worsening systolic marked by reinduction of BMP-7 expression in the col-
hypertension (Fig. 9) and widening of their pulse pres- lecting duct.
sures consistent with increasing loss of vascular pliability.
In further pursuit of the mechanism of the renoprotec-
DISCUSSIONtive actions of BMP-7 therapy, we reasoned that a critical
pathogenetic action of diabetes might be induced loss of The data presented here demonstrate that the long-
term model of STZ-induced diabetes is associated withexpression of a key differentiation factors, such as BMP-7,
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Fig. 10. a. A composite of kidney in situ hybridizations demonstrating loss of bone morphogenic protein-7 (BMP-7) renal expression in diabetes
and restoration with therapy. (A) A kidney section from a 32-week normal control animal. (B) A 32-week diabetic animal treated with BMP-7,
100 g/kg body weight. (C) A 32-week diabetic animal treated with vehicle. (D) A 32-week diabetic animal treated with enalapril. The 32-week
vehicle-treated diabetic kidneys had complete loss of BMP-7 message. Both BMP-7 and enalapril therapy restored the normal distribution of
BMP-7 expression. The levels of BMP-7 message in the BMP-7- and enalapril-treated kidneys appeared to be higher than the normal animals. b.
Glomerular expression of BMP-7 following BMP-7 therapy. Bright and dark field sections demonstrate significant BMP-7 expression in a glomerulus
of a BMP-7–treated animal. These results were consistent in three separate experiments with different kidneys.
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the development of nephropathy and renal failure that enalapril is estimated to be due to the control of systemic
and glomerular hemodynamics [17–19]. BMP-7 did notresembles the clinical course of human diabetic nephrop-
athy associated with type 1 diabetes [22, 23]. By 16 weeks, affect blood pressure until late in the course of the study,
at a time when systolic hypertension was becomingmassive renal hypertrophy, hyperfiltration and protein-
uria were established in our model. At that time, the prominent and vascular calcification was present (Davies
and Hruska, data not published). We interpret theseearliest changes of glomerular mesangial matrix accumu-
lation were detectable as previously reported [15]. Over data to correlate with the actions of BMP-7 to prevent
vascular calcification [29]. The doses of enalapril usedthe ensuing 16 weeks, during the course of the various
therapies utilized herein, diabetic renal injury either pro- here (20 mg/kg) were maximal [1, 13, 30]. They were 20-
to 50-fold greater than the doses used in clinical medi-gressed or was partially reversed. In the vehicle-treated
group, diabetic injury progressed leading to glomerular cine. Preliminary studies demonstrated that there was
no difference in the enalapril response between 5 mg/kgsclerosis, worsening of the proteinuria, the development
of nephrotic syndrome, and the development of renal and 20 mg/kg. Furthermore, we have demonstrated that
addition of enalapril to the drinking water is equallyinsufficiency. The progression of the nephropathy to se-
vere proteinuria and renal insufficiency was due to pro- effective as more arduous means of administering enala-
pril such as intraperitoneal injections and oral/esopha-gression of the diabetic glomerular pathology to the level
of 10% of the glomeruli being sclerotic. This severity of geal gavage (Hruska and Wang, data not published).
Therefore, we conclude that BMP-7 therapy of STZ-disease is similar to previous reports of glomerulosclero-
sis in STZ-induced diabetic nephropathy [12, 16, 24–26]. induced diabetic nephropathy in the rat is at least equally
effective to enalapril therapy.In three groups of diabetic rats, BMP-7 was adminis-
tered twice a week intravenously at 10, 30, and 100 g/kg BMP-7 is a critical renal morphogen that is expressed
in the normal adult kidney and lost through the influencebody weight, respectively. The effects of BMP-7 therapy
were profound. BMP-7 partially restored kidney weights of renal injury as shown here in diabetic nephropathy.
Its therapeutic actions in renal disease appear to be re-toward normal, restored GFR to normal, dose depen-
dently eliminated proteinuria, partially reversed glomer- lated to recapitulation of its developmental actions.
BMP-7 stimulates epithelial differentiation and providesular hypertrophy, reversed the increase in the expanded
interstitial volume, and dose dependently prevented the metanephric mesenchymal survival signal during mor-
phogenesis [4–6]. This is similar to the actions of BMP-7development of glomerular sclerosis. The reversal of re-
nal injury was the mechanism by which kidney weights, during renal tubulointerstitial injury [1]. BMP-7 de-
creases expression of markers of injury response such asglomerular area, and glomerular filtration rate were re-
duced. All of the parameters of nephropathy that were vimentin and 1(I) procollagen, 1(IV) collagen, and it
increases expression of epithelial phenotype markersassessed demonstrated dose ordering in their response
that was small, although present. Only the differences in such as E-cadherin [1, 5, 8, 11, 21] (abstract; Zeisberg M
et al, J Am Soc Nephrol 12:830A, 2001) (Hruska, data noturine albumin excretion and glomerulosclerosis between
the low-dose and high-dose groups achieved statistical published). It prevents tubular epithelial apoptosis lead-
ing to injury prevention and disease resistance [1, 11].significance.
The therapeutic effects of BMP-7 were further charac- BMP-7 is expressed in the Wolffian duct at the time of
ureteric bud development [4]. It continues to be ex-terized by direct comparison to the known therapeutic
actions of enalapril, an angiotensin-converting enzyme pressed in the ureteric bud and the developing collecting
duct throughout development [31]. In addition, BMP-7(ACE) inhibitor. ACE inhibition was first shown to be
a renal disease therapeutic agent in STZ diabetes [15, is expressed in and required for the condensing meta-
nephric mesenchyme at the tip of the ureteric bud and17–19], and it is especially effective in human diabetic
nephropathy [20, 27, 28]. Subsequently, along with angio- in the pretubular aggregates beginning at day 12.5 [4].
BMP-7 expression subsequently disappears from thetensin II type 1 (AT-1) receptor blockade, it has become
the main renal disease therapeutic for slowing progres- comma and S-shaped bodies. In the adult kidney, BMP-7
is expressed in glomerular podocytes, the thick ascendingsion of disease [27, 28]. In the design of the studies re-
ported herein, a treatment of established disease was used. limb, distal tubule, and collecting duct [21]. The strongest
expression is in the collecting duct, especially in the med-High-dose BMP-7 was at least the same as enalapril in
reducing kidney weights, reversing glomerular hypertro- ullary segments. In the absence of BMP-7, condensation
of metanephric mesenchyme is diminished and mesen-phy, reversing proteinuria, maintaining GFR, decreasing
mesangial matrix expansion, decreasing interstitial vol- chymal cells apoptosis between 12 and 14 days post-
coitum [4]. Analogously, in response to renal injuriesume expansion, and preventing the development of glo-
merular sclerosis. Enalapril therapy normalized blood BMP-7 expression is lost, as shown here and elsewhere
[1, 14, 32], and this is a factor in increasing TGF-	 expres-pressure during the entire 16-week course of therapy. An
important component of the therapeutic effectiveness of sion (Hruska, data not published) and promoting epithe-
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